A Review of Current Diagnosis, Investigation, and Management of Acute Coronary Syndromes in Elderly Patients by unknown
REVIEW
A Review of Current Diagnosis, Investigation,
and Management of Acute Coronary Syndromes
in Elderly Patients
Claire McCune . Peter McKavanagh . Ian. B. Menown
To view enhanced content go to www.cardiologytherapy-open.com
Received: June 28, 2015 / Published online: September 22, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
The elderly constitute a sizeable proportion of
the acute coronary syndrome (ACS) population,
and this population is continually increasing in
number. Guideline-directed therapy is
frequently underutilized in the elderly due to
concerns about patient safety. However, studies
suggest that this subgroup could benefit from
many of the conventional and newer therapies
available. This paper reviews current literature
in the context of contemporary American and
European guidance.
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INTRODUCTION
The elderly constitute a significant portion of
the acute coronary syndrome (ACS) population,
with over 75 year olds representing 27–34 % in
European registries [1]. Furthermore, aging
patients are an increasing cohort, with over
85 year olds expected to triple by the year 2035
[2]. This changing epidemiology presents new
difficulties in diagnostic and management
strategies. Cardiovascular medicine is a
continually evolving and progressive
discipline. However, elderly patients are
frequently under-represented in clinical trials,
leading to uncertainty among clinicians about
the relative efficacy and safety of some
treatments in this group and, as a
consequence, they are less likely to receive
evidence-based therapies [3].
Although at higher baseline risk, this
contributes further to the poorer outcomes in
elderly patients compared with younger patient
groups [4]. This paper aims to review and
summarize the latest evidence and guidelines
relevant to managing elderly patients, with
discussion of current patterns of practice and the
obstacles to delivering guideline-directed care.
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CLINICAL CHARACTERISTICS
OF ELDERLY PATIENTS WITH ACS
Mehta et al. analyzed 163,140 hospital
admissions of Medicare beneficiaries age C65
admitted from 1994 to 1996 and subcategorized
these patients by age [5]. Increasing age was
associated with a greater incidence of functional
limitations, heart failure, prior coronary disease,
and renal insufficiency [5]. Conversely, there is
less diabetes and fewer male patients in older
subgroups [5].
Through analysis of five nationwide Italian
registries, De Luca et al. demonstrated the
changing characteristics of the elderly cohort
([75 years of age) admitted to coronary care
units with an acute myocardial infarction over
time from 2001 to 2010 [6]. This showed
increased hypertension, renal dysfunction, and
previous PCI but reduced history of previous
stroke, myocardial infarction, or heart failure
compared to earlier cohorts [6].
DIAGNOSIS AND INITIAL
TREATMENT
Recognition of ACS can be difficult in older
patient groups. This is due a combination of
patient factors with multiple barriers to
diagnosis, but also due to inadequacies in
service provision. Elderly patient groups are
less likely to call emergency services or make
their own way to hospital, and patients aged
over 65 who do contact emergency services
were found to be given a lower priority than
patients aged 51–64 years old [7, 8]. The joint
American Colleges of the American Heart
Association and American College of
Cardiology (AHA/ACC) as well as the
European Society of Cardiology (ESC)
guidelines state that the initial ECG should be
taken within 10 min [9, 10]. However, the
CRUSADE (Can Rapid Risk Stratification of
Unstable Angina Patients Suppress ADverse
Outcomes with Early Implementation of the
ACC/AHA Guidelines) registry highlighted that
elderly patients ([85) on average wait an
additional 7 min before receiving an initial
ECG, and women over 85 were shown to wait
for an average of 45 min [4, 11].
Diagnosis is further delayed by the atypical
presentation of elderly patients as found by the
GRACE (Global Registry of Acute Coronary
Events) registry [12]. Atypical symptoms
included dyspnea in 49%, diaphoresis in 26 %,
nausea or vomiting in 24%, and syncope in 19%
(Fig. 1) [12]. Other confounders to diagnosis
found more frequently in these patients include
Fig. 1 Elderly patients often present with atypical symp-
toms other than chest pain
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silent myocardial infarctions, which account for
up to 60% of infarcts in patients over 85 years
old, and concurrent illnesses such as
pneumonia [4].
Inequalities in care were also found on
admission, with elderly patients less likely to
be admitted to a cardiology ward or under the
care of a consultant cardiologist [13]. This is
likely multifactorial, due to factors such as
delayed diagnosis, atypical presentation,
increased resource requirements, and
prolonged length of stay.
Given that elderly patients with ACS have
poorer outcomes than their younger
counterparts, in part due to the difficulties and
delays in diagnosis, a high index of suspicion in
the elderly population is therefore advised by
European guidelines [10].
ANTIPLATELETS
Antiplatelet agents as recommended for ACS by
AHA/ACC and ESC guidelines are frequently
underprescribed in the elderly [14]. Aspirin
gained United States Food and Drug
Administration approval for use in primary and
secondary prevention of cardiovascular disease
in 1985. There are no trials designed to assess the
effect of aspirin specifically in elderly patients,
and elderly patients are underrepresented in
other studies despite the increased risk of
coronary heart disease and stroke in this group
[15]. Analyses of previous trials have shown that
patients over the age of 65 have a greater
absolute risk reduction and a similar relative
risk reduction in vascular end points than
younger patient cohorts, and a 22% lower
30-day mortality (Fig. 2) [4, 14, 16]. Moreover,
a similar trend of reduced risk of stroke,
myocardial infarction (MI), vascular events, and
death was witnessed in the very elderly
([85 years old) [14, 17].
The GRACE registry demonstrated that age is
independently linked to an increased bleeding
risk in ACS patients. Although many studies
have not shown increased bleeding in these
groups with pharmacotherapy, this is likely due
to patient selection, and concerns remain about
bleeding in elderly groups [14, 17, 18]. This is
further discussed in a review paper by Patrono
et al., who highlight a marked increase in risk of
bleeding complications in patients over the age
of 70 and especially in patients with a history of
gastrointestinal disturbance [15]. The review
paper concludes that it is difficult to assess
whether the possible benefits of aspirin exceed
the risks of upper gastrointestinal bleeding in
this age group [15]. However, current AHA/ACC
and ESC guidelines recommend the initiation of
aspirin in patients with suspected ACS without
contraindications and regardless of their age [4,
9, 10]. The ADAPTABLE trial (Aspirin Dosing: A
Patient-Centric Trial Assessing Benefits and
Long-term Effectiveness) is currently enrolling
high-risk patients (previous myocardial
infarction or significant coronary disease) to
receive lower-dose (81 mg) or higher-dose
(325 mg) aspirin with the aim to assess efficacy
and bleeding risk in patients, comparing older
and younger subgroups [19].
COMMIT (Clopidogrel and Metoprolol in
Myocardial Infarction Trial) and CURE
(Clopidogrel in Unstable Angina to Prevent
Fig. 2 Medical therapies such as aspirin have an important
role in treating many elderly patients
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Recurrent Events) (mean age 64.2 ± 11.3) have
shown that combining aspirin and clopidogrel
is significantly more effective in reducing
composite cardiovascular death (CV), non-fatal
MI (myocardial infarction), or stroke than
aspirin alone [20, 21]. Conversely, the
combination of both drugs offers less benefits
to elderly patients than in younger NSTE-ACS
(non ST elevation myocardial infarction)
patients with similar absolute (2.0% vs. 2.2%)
and smaller relative (13.1% vs. 28.9%) risk
reductions [4, 21, 22]. An exception is in
elderly patients undergoing percutaneous
coronary intervention (PCI) with higher risk
scores or prior revascularization, where older
patients had greater benefit [4, 23]. CURE
showed an increase in the risk of major
bleeding with dual therapy vs. aspirin alone
(3.7% vs. 2.7% placebo; P = 0.001) and a small
although nonsignificant 17% increase in the
risk of life-threatening bleeding (2.1% vs. 1.8%,
P = 0.13) [21]. Some authors suggest the routine
use of proton pump inhibitors (PPI), which have
been shown to decrease the higher incidence of
gastrointestinal bleeding associated with
antiplatelets in older patients [24].
The recent introduction of more potent
P2Y12 antiplatelet agents has raised more
questions in treating the elderly with
NSTE-ACS. Ticagrelor is increasingly used in
the general population, but guidelines provide
limited input with regards to prescription in
elderly patients. PLATO (PLATelet inhibition
and patient Outcomes) showed ticagrelor as
compared with clopidogrel in patients with
acute coronary syndromes (also receiving
aspirin) was associated with significantly
reduced rates of cardiovascular death,
myocardial infarction, or stroke without an
increase in overall major bleeding, although
also with an increase in non-CABG-related
bleeding (Fig. 3) [25]. Notably, this trial used
PLATO definitions of bleeding, with higher
non-CABG major bleeding rates seen when
using TIMI definitions [26]. Additionally, there
was a significant excess of fatal intracranial
bleeding in the ticagrelor group (11 [0.1%] vs. 1
[0.01%], P = 0.02) and excess stroke with
ticagrelor in the STEMI (ST elevation
myocardial infarction) population 1.7% vs.
1.0% (hazard ratio, 1.63; 95% CI, 1.07 to
2.48; P = 0.02) [26, 27]. Lindholm et al. found
no benefit for patients [65 undergoing
Fig. 3 All-cause mortality according to age. a Estimated
event rate at 12 months, ticagrelor vs clopidogrel.
b Treatment effect by patient age. HR hazard ratio, CI
conﬁdence interval. Reproduced with permission from
[29]
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revascularization (interaction P\0.01 vs.
patients\65 years) [28].
In a PLATO substudy of elderly patients
([75 years), while absolute incidences of
vascular events and bleeding events were
higher in the elderly, there was no significant
heterogeneity in the benefit of ticagrelor over
clopidogrel between patients C75 years
(n = 2878) vs. \75 years (n = 15744) with
respect to reduction in composite
cardiovascular death, myocardial infarction, or
stroke (interaction P = 0.56); myocardial
infarction (interaction P = 0.33);
cardiovascular death (interaction P = 0.47);
definite stent thrombosis (interaction
P = 0.81); or all-cause mortality (interaction
P = 0.76) [29]. Similarly, there was no
significant heterogeneity in the small excess of
PLATO-defined non-CABG major bleeding with
ticagrelor vs. clopidogrel between patients
C75 years vs. \75 years (interaction P = 0.98)
(Fig. 4) [29]. A reduced dose of 60 mg twice daily
as an alternative to 90 mg twice daily may be
safer in the elderly as suggested by the
PEGASUS-TIMI 54 (Prevention of
Cardiovascular Events in Patients With Prior
Heart Attack Using Ticagrelor Compared to
Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction
54) trial [30]. Although dyspnea and ventricular
pauses were more frequent overall with
ticagrelor, there was no finding of an
age-related interaction [29].
TRITON–TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with
Prasugrel–Thrombolysis In Myocardial
Infarction 38) compared prasugrel with
clopidogrel in patients with ACS who were
scheduled to have PCI. Patients C75 years old
had only a small (6%), nonsignificant reduction
in the primary efficacy endpoint offset by an
excess of TIMI major bleeding, leading to a
nonsignificant net clinical benefit (hazard ratio,
0.99; 95% CI, 0.81 to 1.21; P = 0.92) [31, 32].
The excess of bleeding with prasugrel showed a
similar relative but greater absolute increase in
the subgroup C75 years and in the subgroup
\60 kg (common in the elderly) [31, 33].
Furthermore, those with a history of stroke or
transient ischemic attack (common in elderly
groups) demonstrated net harm due to
non-CABG-related nonfatal TIMI major
Fig. 4 Overall non-coronary artery bypass graft-related
bleeding according to age. a Estimated event rate at
12 months, ticagrelor vs clopidogrel. b Treatment effect by
age. HR hazard ratio, CI conﬁdence interval. Reproduced
with permission from [29]
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bleeding [31]. Currently, the use of prasugrel in
patients C75 years of age is generally not
recommended, and if undertaken (with
caution after a careful individual benefit/risk
evaluation by the prescribing physician), a
lower maintenance dose of 5 mg should be
used; the 10-mg maintenance dose is not
recommended [10]. History of stroke or
transient ischemic attack is a contraindication
[34]. Research to investigate the use of a reduced
dose of prasugrel includes the secondary
analysis of TRILOGY ACS (TaRgeted platelet
Inhibition to cLarify the Optimal strateGy to
medicallY manage Acute Coronary Syndromes)
and the ongoing Elderly ACS II trial
(ClinicalTrials.gov IDNCT01777503) [35].
ANTICOAGULATION
Multiple studies have shown that
anticoagulation with unfractionated heparin
(UFH) or low molecular weight heparin
(LMWH) can reduce death or MI in NSTE-ACS
[4, 36–43]. However, in elderly patients, there
are very limited data on the efficacy and safety
compared to younger patient subgroups, as
many studies fail to report patient age [43].
Older age may be linked to higher blood levels
of heparin and activated partial thomboplastin
time, as well as higher anti-Xa levels with
renally excreted LMWH [4, 44]. LMWH has
been found to have a more predictable dose
response than UFH, but still may benefit from
dose adjustment according to age, body weight,
and renal function (the latter two may decline
with age) [45].
The SYNERGY (Superior Yield of the New
strategy of Enoxaparin, Revascularization and
GlYcoprotein IIb/IIIa inhibitors) trial
demonstrated a nonsignificant trend of
increased TIMI major and GUSTO (Global
Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries) severe bleeding with enoxaparin
compared with UFH, but similar rates of death
or myocardial infarction in elderly patients [46].
As a consequence, ESC guidelines suggest
reducing the dose adjustment of 1 mg/kg once
daily in patients over 75 years old with
monitoring of anti-Xa levels [10]. In
comparison, the AHA/ACC recommend 1 mg/
kg twice daily with alteration based on individual
patient characteristics, including creatinine
clearance [9]. The direct thrombin inhibitor
fondaparinux, which achieves a relatively low
level of anticoagulation (50% of the anti-Xa level
of enoxaparin at standard doses) was found to
have a lower bleeding risk but a similar efficacy to
enoxaparin in the OASIS 5 (Organization for the
Assessment of Strategies for Ischemic Syndromes
5) trial, even with moderate renal impairment
[47]. However, given the relatively low level of
anticoagulation, top up with unfractionated
heparin is required to reduce the risk of
catheter thrombosis if the patient undergoes
PCI [46].
Anticoagulation may also be required for
additional reasons such as atrial fibrillation.
Atrial fibrillation doubles in prevalence with
each decade of age, reaching almost 9% at
80–89 years old [48]. Unsurprisingly, many
patients that present with NSTE-ACS have
concurrent atrial fibrillation and therefore
warrant consideration for triple therapy
(vitamin K antagonist, aspirin, and a P2Y12
receptor inhibitor); however, this is associated
with a three- to fourfold increase in major
bleeding complications [10]. It has been
demonstrated that oral anticoagulation
increases the risk of intracranial hemorrhage
with increasing age [49]. The complication is of
particular importance due to its higher
mortality rate [49]. The risk is further
increased in patients with hypertension,
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cerebrovascular disease, and with a higher
dosage of anticoagulant [49].
In patients with atrial fibrillation and a
moderate to high risk of stroke, American and
European guidelines advocate bleeding risk
assessment, consideration of stent type (bare
metal vs. drug-eluting stent), and limitation of
triple therapy duration accordingly [9, 10]. The
HAS-BLED (Hypertension, Abnormal Renal/
Liver Function, Stroke, Bleeding History or
Predisposition, Labile INR, Elderly, Drugs/
Alcohol Concomitantly) score may help in
such decision-making and acknowledges the
increased bleeding risk with age [9]. Although
some guidelines advocate the use of a narrower
therapeutic range (2.0–2.5), this has not been
investigated through prospective studies [9].
OTHER THERAPIES
Adjunctive therapies are often underprescribed
in the elderly, including patients with no clear
contraindication. This is likely multifactorial,
due to concerns about polypharmacy, drug
interactions, and a lack of information on the
risk benefit of medications in this population.
High-intensity statin therapy is
recommended for ACS patients who are not
contraindicated by both the ESC and AHA/ACC
guidelines [4, 50]. The PROVE IT (Pravastatin or
Atorvastatin Evaluation and Infection Therapy)
study showed a 16% reduction in death, MI,
stroke, late revascularization or readmission for
unstable angina with high-dose atorvastatin
compared to pravastatin, with this effect
extending to older age groups [51]. PROSPER
(PROspective Study of Pravastatin in the Elderly
at Risk) showed a 15% relative and 2.1% absolute
risk reduction in death or MI in patients over 70
with high-risk features [52]. The CARE
(Cholesterol And Recurrent Events) and LIPID
(Long-term Intervention with Pravastatin in
Ischemic Disease) trials also showed a benefit of
statin use in patients aged 65–75 with a reduced
rate of CAD deaths [53, 54]. In the very elderly
(octogenarian) age group, the value of
lipid-lowering therapy can be more contentious
since randomized data are relatively scarce and
analysis may be confounded by an observational
J-shaped association between cholesterol levels
and all-cause mortality [55]. Nevertheless, the
latest NICE guidance recommends consideration
of statin therapy in those[85 years to reduce the
rate of nonfatal myocardial infarction unless
treatment is deemed inappropriate due to
comorbidity, polypharmacy, general frailty, or
life expectancy [56]. The effect of
angiotensin-converting-enzyme (ACE)
inhibitors has also been studied in older patient
groups. GISSI 3 (Gruppo Italiano per lo Studio
della Sopravvivenza nell’infarto Miocardico) was
a large Italian randomized trial investigating the
use of ACE inhibitors in acute MI patients with
preserved left ventricular function, and included
a large proportion (27%) of elderly patients [57].
This showed that ACE inhibitors post myocardial
infarction reduce combined death, heart failure,
and left ventricular systolic function at 6 months
[57].
The subsequent studies SAVE (Salvage and
Ventricular Enlargement) and AIRE (Acute
Infarction Ramipril Efficacy) have
demonstrated reduced long-term mortality in
elderly patients over 65 years of age after acute
myocardial infarction with reduced left
ventricular function [58, 59]. Krumholz et al.
studied the effect of ACE inhibitors in 14,129
post-MI patients aged 65 and older, and found
that patients who used ACE inhibitors had a
significantly reduced 1-year mortality, with this
benefit also significant within the[80-year-old
subgroup [60].
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Angiotensin receptor blockers have also been
found to benefit outcome post myocardial
infarction in the elderly, albeit with an
increased incidence of side effects compared
with younger patients [61–63].
Aldosterone antagonists can be more
difficult to use in elderly patients, particularly
in the setting of reduced renal function. While
EPHESUS (Eplerenone Post-acute myocardial
infarction Heart failure Efficacy and SUrvival
Study) did demonstrate an efficacy benefit in
elderly patients with left ventricular
dysfunction post MI, there was a samller
benefit of treatment than seen in younger
patients but a higher risk of side effects,
including hyperkalemia [61, 64].
Conversely, beta blockade has been shown to
have a similar beneficial effect in both younger
and elderly subgroups, with decreased mortality
and re-infarction post MI [61, 65–67]. GUSTO-I
and COMMIT showed that patients receiving
early intravenous beta blockade had a higher risk
of an adverse outcome than oral beta-blocker
groups, particularly in elderly STEMI patients
who are at risk of hemodynamic instability and
heart failure [68, 69].
The benefits of current guideline-directed
medical therapies also extend to
nonpharmacological methods.
Cardiac rehabilitation has been shown to
improve exercise capacity, diabetic glucose
control, autonomic function, behavioral
characteristics, quality of life, future
hospitalization costs, and major cardiovascular
morbidity and mortality. Despite having
comparable benefit in both elderly patients
and younger groups, few are still referred [70].
This was further demonstrated by Suaya et al.,
who found that cardiac rehabilitation was used
in only 13.9% of elderly patients (defined as
[65) who survived 30 days after an acute
myocardial infarction and 31% of patients
after bypass surgery [71]. Notably, the most
powerful predictor of patient participation is
physician referral and encouragement [72].
Patients who decline rehabilitation should be
encouraged to exercise for at least 30 min on
most days and preferably for 45 min 4–5 times a
week [72].
Several specific considerations must be made
for elderly patients when considering cardiac
rehabilitation. It is important to assess each
individual’s physical capability and consider
the variations in physiology patients
experience with age; for example, elderly
patients could benefit from a longer warm-up
time [73]. Moreover, an appropriate
cooling-down period is particularly important
to prevent hypotension (secondary to a delayed
baroreceptor response post exercise) [73].
REVASCULARIZATION
Due to a growing elderly population with a high
prevalence of coronary disease, the question of
whether to revascularize and the strategy of
choice is becoming increasingly relevant. At
present, research is limited regarding outcomes
of elderly patients receiving revascularization
therapies, as many major trials fail to enroll
elderly subgroups [4, 61].
The merits of revascularization have been
shown in elderly patients with symptomatic
stable ischemic heart disease. TIME (Trial of
Invasive versus Medical therapy in Elderly
patients with chronic symptomatic coronary
artery disease) randomized 305 patients aged 75
and above with chronic angina (despite being
treated with two antianginal medications) to
revascularization vs. medical therapy only [74].
Patients in the revascularization group showed
symptom relief and improved quality of life,
with a reduction in the composite of death/MI/
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readmission with ACS at 6 months (49%
medical vs. 19% revascularization (P\0.0001)
[70]. The large although observational
APPROACH (Alberta Provincial Project for
Outcome Assessment in Coronary Heart
Disease) registry compared 4-year outcomes
among 21,573 patients undergoing diagnostic
cardiac catheterization. Those 70–79 years of
age and, particularly, those C80 years of age
showed greater adjusted reductions in death
with revascularization compared with medical
therapy than in those\70 years of age [75].
Furthermore, the benefits of
revascularization may extend into elderly
subgroups with NSTE-ACS. FRISC II (Fragmin
and fast Revascularization during InStability in
Coronary artery disease) was a randomized
controlled trial comparing initial conservative
treatment to an invasive strategy (within 7 days
from admission) in patients with NSTE-ACS
[76]. At 6 months, the invasive strategy was
associated with a lower rate of death or MI (in
patients who were troponin positive or with ST
changes); the benefit being sustained out to
5 years [76]. While FRISC II excluded patients
[75 years old, those aged 65–75 years showed a
greater absolute reduction in composite death
or MI with an invasive treatment strategy
compared with patients\65 years of age [76].
The TACTICS-TIMI 18 (Treat Angina with
Aggrastat and Determine Cost of Therapy with
an Invasive or Conservative Strategy) trial is
frequently quoted in clinical guidelines, as it
was one of the first to establish that patients
presenting with non ST elevation ACS assigned
to an early invasive strategy had a reduction in
incidence of the composite of death, MI, or
readmission with ACS compared with those
treated by a conservative strategy [77]. Less well
known is that the significant reduction in death
or MI achieved with an invasive strategy was
confined to those C65 years of age (8.8% vs.
13.6%; P = 0.018), and no significant difference
was seen in those\65 years of age (6.1% vs.
6.5%; P[0.2) [78]. This benefit was even greater
in those[75 years (10.8% vs. 21.6%; P = 0.016),
albeit with higher major bleeding rates (16.6%
vs. 6.5%; P = 0.009), likely exacerbated by the
protocol-mandated use of glycoprotein IIb/IIIa
inhibitor in both arms [78]. Savonitto et al.
investigated 313 patients aged 75 years and
over, randomly allocating them to an early
aggressive strategy (angiography with
revascularization if indicated within 72 h) vs.
an initially conservative strategy (angiography
and revascularization only for patients with
recurrent ischemia) [79]. The primary endpoint
included death, myocardial infarction,
disabling stroke, repeat hospital stay for
cardiovascular cause, or severe bleeding within
1 year [79]. The primary endpoint occurred in
27.9% (43) of patients undergoing an early
aggressive strategy compared to 34.6% (55) of
the initial conservative group (hazard ratio,
0.80; 95% CI, 0.53–1.19; P = 0.26) [79]. There
was no significant difference in the rates of
mortality, myocardial infarction, and
readmission between each group [79]. Patients
with normal troponin levels on admission had
no benefit from an early aggressive approach,
but those with elevated troponin had a
significant 57% reduction in the primary
endpoint rate (P for interaction: 0.0375) [79].
Choice of Revascularization Strategy
Factors such as morbidity, mortality, and
complications should be considered when
deciding upon the most appropriate
revascularization strategy [9, 10]. Initial studies
of PCI in elderly subgroups demonstrated an
increased risk of complications; however, as
technology and techniques have improved over
time, this risk has decreased, with high numbers
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of elderly patients undergoing PCI (Fig. 5) [6].
Furthermore, elderly PCI is increasingly being
performed in patients with multiple
comorbidities without a significant change in
risk, as demonstrated in the Scottish Coronary
Revascularization Register [80].
The choice of strategy can be more complex
when considering patients with multivessel and
left mainstem disease. This finding is more
prevalent in elderly populations, who also
tend to have higher levels of comorbidity.
CABG often achieves complete
revascularization but may entail prolonged
postoperative recovery in elderly patients,
whereas PCI may enable same or next-day
discharge, early recovery, and potentially a
quicker improvement in quality of life.
The mortality benefits of revascularization
strategies have been investigated in multiple
observational studies. Weintraub et al.
compared CABG versus PCI in patients
[65 years of age with multivessel disease, and
found a similar mortality at 1 year but improved
survival, reduced stroke, and MI at 4 years for
CABG patients [81].
Dacey et al. undertook a review of 1693
octogenarians (80–89 years) undergoing
revascularization for two- or three-vessel
disease between 1992 and 2001. CABG
(predominantly on pump) was associated with
higher in-hospital and 6-month mortality
compared to PCI but improved survival from
6 months to 8 years [82].
In a small observational study, Sheridan et al.
found that, even in the very elderly (aged 85
and over), while PCI was associated with
improved early survival, CABG was associated
with a small improvement in survival by
36 months (66% vs. 63%, P\0.05), although
it was noted that the CABG patients were highly
selected: they were without congestive heart
failure, pulmonary disease, or peripheral
vascular disease [83]. Appropriate patient
selection for CABG is very important,
particularly in the elderly. Alexander et al.
showed that 30-day mortality post-CABG was
markedly higher in elderly patients overall
(8.1% vs. 3% in younger patients), whereas
elderly patients without significant comorbidity
had a 30-day mortality of 4%—approaching
that of their younger counterparts [84].
In an analysis of ten trials, Hlatky et al.
suggested that CABG confers a mortality benefit
specifically in diabetic patients [65 years in
comparison to PCI [85]. A systematic review of
66 studies (65 observational) concluded that
revascularization could be performed in
octogenarians with acceptable short- and
long-term outcomes, but definite conclusions
could not be drawn regarding survival benefit
given the paucity of current data [85].
Although these studies suggest that elderly
patients free from comorbidity have
postoperative outcomes approaching those of
a younger age group, a more robust method of
identifying these patients is required. This could
allow a better understanding of the risks and
benefits for both the patient and the medical
team. Additionally, the risk of postoperative
Fig. 5 Choice of revascularization strategy in elderly
patients over the past decade from 5 nationwide Italian
registries. Reproduced from [6]
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complications may take precedence over
mortality risk. Alexander et al. showed that
octogenarians have an increased risk of
neurological and renal complications (twice
the rate of younger patients) [84]. On
reviewing 88,154 patients after CABG (43,369
aged 65–79, 8170 patients over 80 years),
Bardakci et al. concluded that although early
outcomes of octogenarians are acceptable, there
are ‘‘strikingly lower discharge to home rates,’’
and that long-term quality of life data in this
age group are required [86].
These studies have suggested several potential
benefits of revascularization. However, the
majority of evidence is observational and based
on selected elderly patients. Evidence for CABG
in multivessel disease has so far demonstrated
increased long-term freedom fromcardiac events
and improvement in symptoms. Nevertheless,
with increased morbidity and mortality in the
postoperative period, a longer recuperation time,
and increased risk of long-term cognitive
impairment (1 in 5 patients), surgical
revascularization may not be an acceptable risk
to the individual patient.
Current AHA/ACC guidelines state it is
reasonable to choose CABG over PCI in
NSTE-ACS patients, particularly in diabetics or
in those with complex triple vessel disease, to
reduce cardiovascular disease events and
readmission and to improve survival (IIa level
B) [9]. ESC guidelines state that the elderly
should be considered for an early invasive
strategy with the option of revascularization
after carefully weighing up the risks and
benefits (IIa level B) [11].
STEMI
The disadvantages incurred by the elderly with
NSTE-ACS are paralleled in elderly STEMI
patients by a higher likelihood of delayed or
atypical presentation [77]. In addition, many
elderly patients have pre-existing LBBB which
may confound patient diagnosis [77]. Multiple
trials regarding oral pharmacotherapy in acute
myocardial infarction do not differentiate
between STEMI and NSTEMI; this is therefore
addressed separately (also refer to Table 1).
Due to concerns regarding increased
hemorrhagic risk, multiple thrombolysis trials
excluded elderly patients; however, the survival
benefit from reperfusion in STEMI patients
found in GUSTO I, ISIS-2, and GISSI studies
extended to elderly subgroups [87–90]. Berger
et al. showed a benefit in 1-year mortality (but
not 30-day survival) in selected thrombolysis
patients [91]. In clinical practice, thrombolysis
has often been underutilized in the elderly,
likely due to concerns about risk of intracranial
hemorrhage and nonhemorrhagic stroke
(especially in the very elderly), despite the
greater absolute benefit in this population [77,
92]. Furthermore, the adjunctive administration
of pre-hospital enoxaparin at a standard dose
was associated with an increased rate of
intracranial hemorrhage in elderly patients in
the ASSENT-3 (ASsessment of the Safety and
Efficacy of a New Thrombolytic) PLUS trial [93].
The Enoxaparin and Thrombolysis Reperfusion
for Acute Myocardial Infarction Treatment
(ExTRACT)—Thrombolysis In Myocardial
Infarction (TIMI) 25 trial compared the use of
adjunctive enoxaparin to unfractionated
heparin in patients receiving thrombolysis
[94]. An alternative regimen of enoxaparin
administration was devised for patients aged
[75, and involved omitting the initial loading
dose and reducing subsequent subcutaneous
doses to 0.75 mg/kg every 12 h (with a
maximum dose of 75 mg) [94]. This trial
showed a reduction in the primary endpoint
(composite death from any cause or nonfatal
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Table 1 Summarizing current evidence and guidelines for elderly ACS patients





ISIS-2 RCT ↓ risk of vascular events, CVA, non fatal MI and CV death in general population[90]
GRACE registry- Bleeding risk ↑ with age[18]
Krumholz et al, retrospective observational (aged >65 years)MI
No significant excess bleeding (undefined) 139/6140 (2.3%) aspirin vs. 122/3878 (3.2%) 
22% ↓ 30 day mortality if given within 48 hours
14% aspirin (860/6140) vs. 24.3% (943/3878) OR, 0.78; 95% CI 0.70 to 0.89, P=<0.0001[14]
Ongoing ADAPTABLE trial- is lower loading dose (81mg) as efficacious?[19]
Treatment decisions in the 
elderly (>75 years) should be 
made in the context of 
estimated life expectancy, 
co-morbidities, quality of 
life, and patient wishes and 
preferences -ESC[10]
Thrombolysis:
loading dose of clopidogrel 









CURE (mean age 64.2 +/-11.3) (19% age >75) RCT double blind NSTE-ACS
↔AR, ↓RR reductions for aspirin/clopidogrel combination not having PCI[21]
↑ major bleeding 3.7% clopidogrel vs. 2.7% P=0.001 RR:1.38[21]
> 65 years subgroup CV death or MI RR 0.79 clopidogrel vs. placebo 95% CI 0.57-1.08[22]
All age groups- death from CV cause, nonfatal MI or stroke 9.3% vs. 11.4% P<0.001 RR:0.80,
CI:0.72-0.90[22]
Benefit in patients receiving PCI with higher TIMI score or prior revascularization[23]
COMMIT (26% age >75) RCT double blind STEMI  
↓death, reinfarction or CVA 9.2% vs. 10.1% placebo P=0.002







PLATO RCT ticagrelor vs. clopidogrel NSTE-ACS (16% age >75) 
Significantly ↓primary outcome composite vascular death, MI or CVA 9.8% clopidogrel vs. 11.7% 
(HR, 0.84; CI: 0.77-0.92, P<0.001)[25]
No increased benefit in patients >65 years old undergoing revascularization (interaction p<0.01 vs. 
patients <65 years)[28]
PLATO ≥75 subgroup analysis 2878 patients
Primary outcome 17.2% vs.18.3% in clopidogrel group  (HR, 0.89; 95% CI 0.74–1.08)
↔ benefit for age ≥75 vs. <75 (P=0.56 for interaction)
↔ of definite stent thrombosis and all cause mortality[29]
↑ numbers of fatal intracranial bleeding  (11 (0.1%) vs. 1 (0.01%), P=0.02)
Small excess non-CABG-related bleeding (PLATO defined)(4.5% vs. 3.8%, P=0.03)
Dyspnea and ventricular pauses increased (not age dependent)[25]
PEGASUS is currently investigating use of reduced dose ticagrelor[30]











Multiple trials show ↓ death or MI with UFH/LMWH in NSTE-ACS[36-42] 
 
SYNERGY (25.5%  age ≥75) RCT NSTE-ACS enoxaparin vs. UFH 
High risk patients who received invasive management  
↔ enoxaparin  vs. UFH for death or MI at 30 days  
↑ TIMI major bleeding[99] 
 
SYNERGY Subgroup analysis age ≥75 
↔ death or MI between UFH and LMWH groups 
Higher, non significant increase in bleeding and transfusion rates in elderly enoxaparin group[46] 
 
OASIS-5 RCT NSTE-ACS (Average age 66.6 (+/- 10.8-11) fondaparinux vs. enoxaparin 
Bleeding risk (217 events (2.2%) vs. 412 events (4.1%); HR, 0.52; P<0.001) but similar efficacy of 
fondaparinux vs. enoxaparin[47] 
 
Special attention must be 
given to proper dosing of 
antithrombotics in elderly 




enoxaparin omit iv bolus; 
start with first sc dose of 0.75 
mg/kg with a maximum of 75 









PROVE IT RCT 30% of cohort ≥65 years. High dose atorvastatin vs. pravastatin in ACS 
26.3% vs. 22.4% (↓16% reduction in HR P=0.005;95% CI, 5-26%) reached primary endpoint of 
composite death, MI, CVA, late revascularization or readmission for unstable angina 
Findings extended to elderly subgroup[51]  
Most studies show mortality benefit (many not based on ACS patients)[52-54] 
 
Most evidence for ACS patients extrapolated from studies in younger age groups 
 
In the very elderly there is less evidence and one paper showed a possible association with harm in 
patients ≥80 years without CV disease[55] 
 
 
Consider use of lower 
intensity statin therapy in 
patients at increased risk of 








Not recommended in ≥75 
year olds (or <60 kg or prior 
CVA/TIA) in both European 
and American guidelines[50, 
95]
If used a similar loading dose 
but a reduced maintenance 







TRITON-TIMI 38 RCT prasugrel vs. clopidogrel 
Subgroup age ≥75, bodyweight <60kg or history of stroke or TIA
Non significant reduction in the primary efficacy endpoint (death from CV cause, non fatal MI or non 
fatal stroke) 16.1% vs. 16% clopidogrel (HR, 1.02 (0.84-1.24) P=0.83)[31]
Similar relative but greater absolute ↑ in bleeding
Non CABG related TIMI major bleeding 4.3% vs. 3.3% clopidogrel (HR, 1.42 (0.93-2.15), P=0.1)
Spontaneous fatal hemorrhage 9 vs. 0 with clopidogrel
Death from any cause, non fatal MI, non fatal CVA or non CABG related non fatal TIMI major 
bleeding 20.2% vs. 19% (HR 1.07(0.90-1.28), P=0.43)
No significant net clinical benefit (HR, 0.99; 95% CI 0.81 to 1.21, P=0.92)[31-32]
Ongoing research with secondary analysis of TRILOGY ACS and Elderly ACS II trials.
Current Evidence, Risks and Benefits Guideline






















FRISC II RCT NSTE-ACS Initial conservative(I.C) vs. invasive strategy excluded >75 year olds
Aged 65-75 reduction in composite death and MI with an I.C. strategy compared to age <65[76]
TACTICS TIMI 18 RCT Initial conservative vs. early invasive (E.I.)(angiography =+/- at 4-48 hours)
Significant ↓ death or MI with E.I. 
≥65 years 8.8% vs. 13.6%; P=0.018
≥75 years 10.8% vs. 21.6%; P=0.06 ↑ bleeding 16.6% vs. 6.5% P=0.09[78]
Damman et al. Meta-analyses of FRISC II, ICTUS and RITA-3. NSTE-ACS.
Differing definitions of "routine invasive". Routine invasive strategy significantly reduced 5 year 
MACE in 65-74 and ≥75 but not in those <65 years. Significantly ↑ in hospital bleeding in older 
patients[101]
Savonitto et al. RCT n=313 ≥75 years. NSTE-ACS  Initial conservative vs. early aggressive (<72 
hours)
Non significant primary endpoint occurred in 27.9% early aggressive vs. 34.6% initial conservative 
(for death, MI, disabling stroke, repeat hospital stay for CV cause or severe bleeding within 1 year) 
(HR, 0.80; 95% CI, 0.53-1.19, P=0.26)
However elderly patients with a troponin rise had a 57% ↓ in primary endpoint (P for interaction= 
0.0375)[79]
Older patients with NSTE-
ACS should be treated with 




Management decisions for 
older patients with NSTE-
ACS should be patient 
centered, and consider 
patient preferences/goals, co 
morbidities, functional and 











Pharmacotherapy in older 
patients should be 
individualized and dose 
adjusted by weight and/or 
creatinine clearance to reduce 
adverse events caused by 
age-related changes in 
pharmacokinetics/dynamics, 
volume of distribution, co 
morbidities, drug 













GISSI 3 RCT (27% aged ≥70)  post MI.  lisinopril vs. open control 
↓ 30.6% vs. 33.8% (OR, 0.86; 95% CI 0.77-0.97, P=0.01) combined death, heart failure and left 
ventricular systolic function at 6 months[57] 
 
SAVE/ AIRE reduced long term mortality in ≥65 post MI with reduced left ventricular function[58-
59] 
 
Krumholz et al. retrospective observational, ace-i post-MI n= 14,129 ≥65 years (29% ≥80 years) 
↓1 year mortality, adjusted risk ratio 0.85 (95% CI, 0.77-0.93, P=0.001) 








OPTIMAAL RCT, high risk post acute MI losartan vs. captopril 
All cause mortality ↓ in ace-i group (non significant) and fewer discontinuations in ARB group[62] 
 
UMPIRE observational, NSTE-ACS aged ≥65 years ARB vs. ace-i  














s    
EPHESUS RCT Post MI average age 64 years (+/-12)  











Soumerai et al. Retrospective observational >65 year olds 3737/5332 eligible for beta blockade 
43%↓ mortality RR, 0.57; 95% CI, 0.47-0.69 
22%↓ hospitalization RR, 0.78; 95% CI, 0.67-0.90[65] 
 
Krumholz et al. Retrospective observational ≥65 years eligible for beta blockade 
↓ inpatient mortality with beta blockade odds ratio, 0.81 (95% CI, 0.75 to 0.87)[66] 
 
Park et al. Retrospective observational 60-89 years old receiving oral metoprolol post MI 
Age adjusted mortality reduction 76% RR,0.24; P<0.001, 95% CI 0.11-0.54[67] 
 
COMMIT early initiation ↑ risk of cardiogenic shock[69] 
 
Current Evidence, Risks and Benefits Guideline
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recurrent myocardial infarction in the first
30 days after randomization) with enoxaparin
compared to unfractionated heparin in all
subgroups [94]. The enoxaparin group
experienced a higher rate of TIMI major
bleeding (including intracranial hemorrhage)
at 30 days [94]. This reduced dosing regimen is
suggested by current ESC guidelines for patients
Table 1 continued
It is reasonable to choose 
CABG over PCI in older 
patients with NSTE-ACS 
who are appropriate 
candidates, particularly those 
with diabetes mellitus or 
complex 3-vessel CAD (e.g. 
SYNTAX score >22), with or 
without involvement of the 
proximal LAD artery, to 
reduce cardiovascular disease 










Dacey et al. Observational. CABG vs. PCI for 2 or 3 vessel disease in patients aged ≥80
CABG ↑ early in hospital mortality, but later ↑ survival 6 months to 8 years. Quality of life not 
assessed[82]
Sheridan et al. Observational. n=10,141 selected NSTE-ACS with multivessel disease aged  ≥85 years 
PCI ↑early survival however CABG ↑ survival at 36 months (66% vs. 63%, P=< 0.05) 
46.1% of CABG recipients were free from composite outcome (vs. 38.7% PCI P< 0.01) ) (highly 
selected low comorbidity)[83]
Alexander et al. Observational. CABG in 4306 patients >80 years (25.3% had MI ≤21 days to 
surgery)
↑ 30 day mortality 8.1% (95% CI 7.3-8.9) vs. 3% younger patients (95% CI 2.9-3.2)
All neurological events 10.2% (vs. 4.2%), CVA alone 3.9% (vs. 1.8%), renal failure 6.9% (vs. 2.9%), 
perioperative MI 2.5% (vs. 1.7%), post-procedural length of stay 7 days (6,11) (vs. 6 (5,8)). P=<0.05















GISSI RCT subgroup selected patients aged >75 years:
trend toward ↓ mortality with streptokinase versus control
28.9% vs. 33.1% at 21 days
43.1% vs. 46.1% at 1 year[89]
de Boer et al. RCT >75 years old, n=75, angioplasty vs. lysis
Primary end point (composite of death, reinfarction or stroke)
30 days 9% vs. 29% lysis group (P= 0.01, RR: 4.3, 95% CI: 1.2- 20.0) 
1 year corresponding figures 6 (13%) and 18 (44%), respectively (P=0.001, RR: 5.2, 95% CI: 1.7-
18.1)[96]
TRIANA RCT n=266 primary PCI vs. thrombolysis an age ≥75
Discontinued early due to slow recruitment.
Primary endpoint (composite all cause mortality, reinfarction, disabling CVA at 30 days) primary PCI 
18.9% vs. 25.4% in the lysis arm OR, 0.69; 95% CI 0.38-1.23; P=0.21 
↓ Recurrent ischemia in primary PCI-treated patients (0.8 vs. 9.7%, P< 0.001)
No differences were found in major bleeds[97]
Pooled analysis with 2 prior trials showed an advantage of primary PCI over lysis in reducing death, 
re-infarction, or CVA at 30 days (OR, 0.64; 95% CI 0.45-0.91)[97]
Current Evidence, Risks and Benefits Guideline
ACS acute coronary syndrome, ACCF/AHA American College of Cardiology Foundation/American Heart Foundation,
AHA/ACC American Heart Association/American Heart Association, AR absolute risk, ARB angiotensin receptor blocker,
CABG coronary artery bypass graft, CAD coronary artery disease, CI conﬁdence interval, CV cardiovascular, CVA
cerebrovascular accident, ESC European Cardiac Society, GDMT guideline-directed medical therapy, HR hazard ratio, iv
intravenous, kg kilograms, mg milligrams, LAD left anterior descending, MI myocardial infarction, NSTE-ACS non ST
elevation acute coronary syndrome, OR odds ratio, P p value, PCI percutaneous coronary intervention, RCT randomized
controlled trial, RR relative risk, sc subcutaneous, STEMI ST elevation myocardial infarction, SYNTAX Synergy between
Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery, TIA transient ischemic attack, TIMI thrombolysis in
myocardial infarction, UFH unfractionated heparin
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over 75 years old as an adjunct to thrombolysis
(i.e., patients selected to be appropriate for lysis
and who do not have access to primary PCI
within 120 min of first medical contact) [95].
Current American guidelines state that LMWH
should not be used as an alternative to
unfractionated heparin in patients over the
age of 75 who are receiving fibrinolytics [50].
In Europe, thrombolysis has largely been
superseded by primary PCI, and multiple small
trials have reduced death, reinfarction, and CVA
in elderly patients with PCI vs. thrombolysis,
consistent with results in younger patients [88,
91, 96, 97]. However, despite the availability of
primary PCI, elderly patients with STEMI still
experience inequalities in care. The CRUSADE
initiative reported that there was no attempt to
administer reperfusion therapy in 7.2% of
non-contraindicated STEMI patients, with
reasons cited including older age, female
gender, and comorbidity, and such patients
had greater in-hospital mortality [98]. AHA/
ACC guidelines state that age alone should not
disqualify a patient from early
revascularization. Instead, we should use
individual judgment based on comorbidities,
functional status, and patient directives [47].
CONCLUSION
Whilst newer guidelines acknowledge the
rapidly increasing elderly population and its
ensuing challenges, it is difficult to create an
all-encompassing guideline for such a varied
population. Diversity in patient characteristics
such as frailty, baseline function, comorbidity,
and cognition presents a unique challenge.
Biological and chronological ages can differ,
and it is therefore the physician’s duty not to
base treatment choices on age alone.
Furthermore, the term ‘‘elderly’’ can cover a
period of several decades from 65 years old on—
a period during which there are marked changes
in patient physiology.
Underrepresentation in trials has led to a
comparative lack of evidence and, although
there are increasing efforts to complete phase 4
trials in the elderly population, we are still left
with questions about how we should best treat
our elderly patients.
American and European guidelines
emphasize the importance of considering the
individual patient. Efforts to comply with
current guidance developed from trials in
younger cohorts could lead to maleficence
such as bleeding or renal failure, so many
physicians omit therapy. Conversely, omission
of treatment could likewise harm a patient who
may otherwise benefit.
Efforts must be made to improve vigilance
and recognition of atypical presentation in
elderly patients. It is important to collect
accurate information promptly which can
then be used to judge each patient’s suitability
for treatment, and not to bias our decisions
based on age alone. Furthermore, it is
imperative that we facilitate an informed
decision-making process for the patient,
adapting the information we convey to the
individual.
Guideline-directed medical therapy should
be considered in the context of the individual
patient, with clear reasons for proceeding with
(benefits exceed risks) or omitting (risks exceed
benefits) treatment. The final decision should
be based on current evidence, physician
judgment, and patient preference.
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